266 related articles for article (PubMed ID: 37080710)
1. The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors.
Piccinelli S; Romee R; Shapiro RM
Semin Hematol; 2023 Jan; 60(1):42-51. PubMed ID: 37080710
[TBL] [Abstract][Full Text] [Related]
2. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
3. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
4. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells: a promising immunotherapy for cancer.
Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
Lian G; Mak TS; Yu X; Lan HY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
[TBL] [Abstract][Full Text] [Related]
7. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
8. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
9. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
10. NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential.
Portale F; Di Mitri D
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298470
[TBL] [Abstract][Full Text] [Related]
11. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
12. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
Kaweme NM; Zhou F
Front Immunol; 2021; 12():683381. PubMed ID: 34220833
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
14. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
15. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
16. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
17. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
19. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
20. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]